Glenmark Gets USFDA Nod For Oral Contraceptive Drug; Shares Up

Posted By:

Glenmark Pharmaceuticals today said it has received final approval from the US health regulator to sell oral contraceptive -- drospirenone and ethinyl estradiol tablets -- in the US market.

The shares were up a huge 4 per cent following the reports of the approval and were last trading at Rs 1209.

Glenmark Gets USFDA Nod For Oral Contraceptive Drug; Shares Up
Glenmark Pharmaceuticals: Quotes, News
BSE 944.05BSE Quote6.55 (0.69%)
NSE 950.40NSE Quote10.55 (1.11%)
"Glenmark Pharmaceuticals Inc., USA has been granted final approval by the United States Food & Drug Administration (USFDA) for Drospirenone and Ethinyl Estradiol tablets USP, 3 mg/0.02 mg," the company said in a BSE filing.

The product is generic version Bayer's Yaz tablets. Glenmark said it plans to commence shipping of drospirenone and ethinyl Estradiol tablets immediately. Citing IMS Health sales data, the company said for the 12 months period ending June, "the Yaz market achieved annual sales of approximately USD 170.1 million". Glenmark's shares were trading at Rs 1,213.65 apiece, up 4.62 per cent from their previous close on BSE.

With inputs from PTI

Read more about: glenmark, us fda
Please Wait while comments are loading...
Company Search
Enter the first few characters of the company's name or the NSE symbol or BSE code and click 'Go'

Thousands of Goodreturn readers receive our evening newsletter.
Have you subscribed?